# Cencora, Inc. (COR) financials

Cencora, Inc. reported revenue of $321.3 billion for fiscal year 2025 (the twelve months to 30 Sep 2025), up 9.3% from fiscal 2024. Net income was $1.55 billion and diluted earnings per share $7.96.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Jun 2026), revenue was $84.8 billion, up 5.1% from a year earlier.

Source: Cencora, Inc.'s annual and quarterly reports, compiled and checked by AapWire. Latest report filed 5 Aug 2026. Amounts in USD. Page: https://aapwire.com/stocks/COR. Retrieved 2026-11-16.

## Latest results: Q4 FY2026

Cencora, Inc. reported revenue of $88.4 billion, up 5.5% from a year earlier, net income of $519 million and diluted earnings per share of $2.71 against −$1.74 for the fourth quarter of fiscal 2026 (the three months to 30 Sep 2026).

Announced in its earnings release of 4 Nov 2026; the quarterly report has not been filed yet, and its figures replace these when it is.

| Measure | Q4 FY2026 | Q4 FY2025 | Change |
| --- | ---: | ---: | ---: |
| Revenue | $88.35B | $83.73B | +5.5% |
| Operating income | $906.8M | $18.50M | +4801% |
| Operating margin | 1.0% | 0.0% | +1.0 pts |
| Net income | $519.4M | −$339.7M | — |
| Diluted EPS | $2.71 | −$1.74 | — |
| Operating cash flow | $3.10B | $3.13B | −1.0% |
| Capital expenditure | $398.5M | $249.8M | +59.5% |
| Free cash flow | $2.70B | $2.88B | −6.2% |

Page: https://aapwire.com/stocks/COR/earnings

## Annual figures (fiscal years)

| Measure | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $146.8B | $153.1B | $167.9B | $179.6B | $189.9B | $214.0B | $238.6B | $262.2B | $294.0B | $321.3B |
| Revenue growth | +8.0% | +4.3% | +9.7% | +6.9% | +5.7% | +12.7% | +11.5% | +9.9% | +12.1% | +9.3% |
| Gross profit | $4.27B | $4.55B | $4.61B | $5.14B | $5.19B | $6.94B | $8.30B | $8.96B | $9.91B | $11.48B |
| Operating income | $1.53B | $1.06B | $1.44B | $1.11B | −$5.14B | $2.35B | $2.37B | $2.34B | $2.18B | $2.63B |
| Net income | $1.43B | $364.5M | $1.66B | $855.4M | −$3.41B | $1.54B | $1.70B | $1.75B | $1.51B | $1.55B |
| Diluted EPS | $6.32 | $1.64 | $7.53 | $4.04 | −$16.65 | $7.39 | $8.04 | $8.53 | $7.53 | $7.96 |
| Operating cash flow | $3.18B | $1.50B | $1.41B | $2.34B | $2.21B | $2.67B | $2.70B | $3.91B | $3.48B | $3.88B |
| Capital expenditure | $464.6M | $466.4M | $336.4M | $310.2M | $369.7M | $438.2M | $496.3M | $458.4M | $487.2M | $668.0M |
| Free cash flow | $2.71B | $1.04B | $1.07B | $2.03B | $1.84B | $2.23B | $2.21B | $3.45B | $3.00B | $3.21B |
| Gross margin | 2.9% | 3.0% | 2.7% | 2.9% | 2.7% | 3.2% | 3.5% | 3.4% | 3.4% | 3.6% |
| Operating margin | 1.0% | 0.7% | 0.9% | 0.6% | −2.7% | 1.1% | 1.0% | 0.9% | 0.7% | 0.8% |
| Net margin | 1.0% | 0.2% | 1.0% | 0.5% | −1.8% | 0.7% | 0.7% | 0.7% | 0.5% | 0.5% |
| Cash and equivalents | $2.74B | $2.44B | $2.49B | $3.37B | $4.60B | $2.55B | $3.39B | $2.59B | $3.13B | $4.36B |
| Total debt | $4.19B | $3.44B | $4.17B | $4.07B | $4.50B | $7.51B | $6.73B | $5.89B | $5.62B | $9.33B |
| Shareholders' equity | $2.13B | $2.06B | $2.93B | $2.88B | −$1.02B | $223.4M | −$211.6M | $522.0M | $645.9M | $1.51B |
| Diluted shares | 226M | 222M | 220M | 212M | 205M | 208M | 211M | 205M | 200M | 195M |
| Dividends per share | $1.36 | $1.46 | $1.52 | $1.60 | $1.66 | $1.76 | $1.84 | $1.94 | $2.04 | $2.20 |

## Quarterly figures (last eight fiscal quarters)

| Measure | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $79.05B | $81.49B | $75.45B | $80.66B | $83.73B | $85.93B | $78.36B | $84.75B |
| Revenue, year on year | +14.7% | +12.8% | +10.3% | +8.7% | +5.9% | +5.5% | +3.8% | +5.1% |
| Gross margin | 3.2% | 3.1% | 4.1% | 3.6% | 3.5% | 3.6% | 4.6% | 4.3% |
| Operating income | $126.6M | $706.3M | $1.04B | $867.7M | $18.50M | $760.4M | $1.14B | $1.12B |
| Net income | $3.38M | $488.6M | $717.9M | $687.4M | −$339.7M | $559.6M | $1.64B | $763.5M |
| Diluted EPS | $0.02 | $2.50 | $3.68 | $3.52 | −$1.74 | $2.87 | $8.40 | $3.94 |
| Free cash flow | $818.1M | −$2.82B | $3.22B | −$73.97M | $2.88B | −$2.42B | $1.17B | $2.43B |

## Operating KPIs

| KPI | Latest | Period | Change on a year |
| --- | ---: | --- | --- |
| [Human Health revenue](https://aapwire.com/stocks/COR/kpi/human-health-revenue) | $74.3B | quarter to 30 Sep 2025 | up 5.7% |
| [Alliance Healthcare revenue](https://aapwire.com/stocks/COR/kpi/alliance-healthcare-revenue) | $6.6B | quarter to 30 Jun 2026 | up 6.0% |
| [Animal Health revenue](https://aapwire.com/stocks/COR/kpi/animal-health-revenue) | $1.5B | quarter to 30 Sep 2025 | up 5.6% |
| [U.S. Healthcare Solutions revenue](https://aapwire.com/stocks/COR/kpi/u-s-healthcare-solutions-revenue) | $74.9B | quarter to 30 Jun 2026 | up 4.9% |
| [International Healthcare Solutions revenue](https://aapwire.com/stocks/COR/kpi/international-healthcare-solutions-revenue) | $7.7B | quarter to 30 Jun 2026 | up 5.9% |

## Method

Each period is read from the report the company filed and checked against accounting identities; a figure that does not pass is left blank (—), never estimated. Free cash flow is operating cash flow less capital expenditure. Diluted EPS is as the company reported it, adjusted for later stock splits. Research information only, not investment advice.
